Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/rosuvastatin/valsartan - HK inno.N

Next Previous
Drug Profile

Amlodipine/rosuvastatin/valsartan - HK inno.N

Alternative Names: CJ-30060; EXONE-R

Latest Information Update: 24 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ HealthCare
  • Developer HK inno.N
  • Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperlipidaemia; Hypertension

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 24 Jul 2025 Launched for Hyperlipidaemia in South Korea (PO), before July 2025 (HK inno.N website, July 2025)
  • 24 Jul 2025 Launched for Hypertension in South Korea (PO), before July 2025 (HK inno.N website, July 2025)
  • 14 Oct 2021 No development reported - Phase-III for Hyperlipidaemia in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top